Qingshu Powder Veterinary Grade API is supplied in three milled forms under manufacturer code QSPV-API: standard oral grade with target D90 ≤ 150 µm, micronized grade with target D90 ≤ 45 µm, and parenteral pre-sterile grade with endotoxin-control and particulate-matter limits. The material is intended for incorporation into tablets, capsules, injectable preparations, powders, granules, premixes, and solutions. The release specification includes marker compound assay by HPLC, loss on drying, sulfated ash, heavy metals, particle-size distribution, residual solvent testing, and microbial enumeration. Because the product is a botanical extract matrix rather than a single chemical entity, the assay is expressed as marker content and the manufacturing process must preserve extract equivalency across batches. The powder is not intended for direct administration without further pharmaceutical formulation.

What specification panel governs release of Qingshu Powder Veterinary Grade API across oral and parenteral dosage forms?

The applicable specification set depends on the target jurisdiction and registration route. When the product is released against the Chinese Veterinary Pharmacopoeia 2020 edition, the corresponding general methods and monograph criteria control identity, purity, and microbiological quality. Where no harmonized monograph exists, the manufacturer’s filed specification or the regulatory approval file in the destination country takes precedence. The release panel is divided into identification, marker quantification, foreign matter, drying and ash control, element residues, and microbiological quality. Method validation for the HPLC marker assay follows ICH Q2(R1) or VICH GL2, with linearity, accuracy, precision, and robustness determined across the intended assay range. System suitability requires resolution between adjacent peaks not less than 2.0 and a relative standard deviation from five replicate injections not more than 2.0%. The acceptance window for marker content is normally 95.0–105.0% of declared content. Identification is confirmed against a characterized working standard of the dried extract. Where no commercial certified reference standard exists, the working standard is qualified by mass, retention time, and UV spectrum against the registration file.

The representative release panel is summarized below. Batch-specific certificates of analysis should be consulted for exact limits and for regulatory status in the destination market.

For oral dosage forms a total aerobic count of ≤ 10³ CFU/g is generally acceptable. For injectable-precursor material the count is tightened to ≤ 10² CFU/g, and endotoxin is controlled at ≤ 0.5 EU/mg. Particle size is selected by dosage form: the standard oral grade is used for capsules, powders, granules, and premixes; the micronized grade is required for suspension injections and may be applied in tablet formulations where dissolution rate is a limiting variable.

Tablet and capsule manufacture with Qingshu Powder Veterinary Grade API is normally based on wet granulation rather than direct compression. Direct compression is feasible only for high-weight tablets when the formulation contains at least 35–50% microcrystalline cellulose together with crospovidone or copovidone. The botanical matrix has low compactibility compared with treated mannitol or dibasic calcium phosphate, and its compaction profile is sensitive to moisture. A fluid-bed granulator with inlet air temperature 55–70 °C and product temperature not exceeding 45 °C is used to avoid loss of volatile marker compounds. The dried granule moisture is controlled at ≤ 3.0% before compression on a rotary tablet press with precompression. Hardness is controlled at 60–80 N for film-coated or chewable tablets, and disintegration is tested in water at 37 ± 2 °C with a limit of 15 minutes unless otherwise specified. Capsule filling is performed with the standard oral grade. The micronized grade has reduced flow and should not be used on high-speed dosator machines without a suitable glidant and sufficient flow optimization.

For powders, granules, and premixes the API is incorporated by geometric dilution. The standard oral grade is pre-blended with a small portion of carrier such as corn starch or rice hulls before addition to a ribbon blender. Blender fill volume is maintained at 60–70% of gross capacity, and blend time is determined by content uniformity rather than by fixed mixing duration. Final blend uniformity is assessed by sampling 10 locations and analyzing marker content by HPLC. A relative standard deviation ≤ 5.0% is typically required for homogeneous blends when the formulation contains ≥ 0.5% of the API by weight. At lower inclusion levels, stepwise dilution must be used and segregation during transfer into bulk bags must be verified. The bulk density of the standard grade may range from 0.42 g/mL to 0.55 g/mL; volumetric filling systems should therefore be controlled by weight rather than volume.

When the API is processed into a sterile injectable rather than an oral premix

Parenteral use changes the critical quality attributes of Qingshu Powder Veterinary Grade API. The pre-sterile grade must meet the endotoxin limit of ≤ 0.5 EU/mg, and the manufacturing area must prevent recontamination with pyrogens. Terminal sterilization by moist heat is preferred when the formulation is an aqueous solution or suspension and the marker compounds show acceptable thermal stability. Aseptic filtration through 0.22 µm membranes is applicable only to clarified solutions; suspension injections cannot be sterile-filtered without removing the active botanical fraction. Injectable production is performed in amber borosilicate glass vials to limit UV degradation. The solution pH is maintained at 6.0–7.5, and nitrogen overlay is used to reduce oxidative browning. Subvisible particulate control must meet the limit of ≤ 6000 particles ≥ 10 µm and ≤ 600 particles ≥ 25 µm per container when tested by CVP 2020 or USP <787>. Because published data for this specific botanical injection is limited, photostability according to ICH Q1B and forced-degradation studies must be generated for each formulation.

Drinking water solution stability boundaries and preservative compatibility

Oral solutions containing Qingshu Powder Veterinary Grade API are prepared as concentrates and diluted before administration. The powder is dispersed in purified water with 10–30% propylene glycol or glycerin as co-solvent; solubility of the marker fraction is pH-dependent and may decrease in hard water. Sodium benzoate at 0.1% and potassium sorbate at 0.1% are common preservatives for non-sterile oral solutions, but preservative efficacy must be verified by CVP 2020 or USP <51>. The final drinking water dilution is typically between 1:1000 and 1:5000 depending on species and body weight. If no preservative system is validated, the diluted solution should be used within 24 hours. Precipitation may occur when water hardness exceeds 300 mg/L CaCO₃; compatibility with chelating agents is not automatic and must be assessed in the stability protocol. The concentrate is stored in amber HDPE containers at or below 25 °C to reduce photodegradation and microbial growth.

Differences in release controls and handling relative to feed-grade botanicals

Qingshu Powder Veterinary Grade API is not interchangeable with feed-grade Qingshu powder. Feed-grade material is released against nutritional or zootechnical parameters and may not carry a full pharmacopoeia microbial panel or marker assay. Veterinary API grade is released under a batch-specific certificate of analysis, with residual solvent limits where applicable, heavy metal limits, and specified particle-size distribution. Compared with single-entity chemical APIs such as amoxicillin trihydrate or enrofloxacin, this product is a multi-component extract matrix. Its dose is defined by marker content and extract equivalency rather than molar purity. It is more hygroscopic than many crystalline APIs; pre-drying at high temperature is not recommended because volatile marker components may be lost. Where moisture removal is necessary, vacuum drying at 60–70 °C and residual pressure ≤ 10 kPa is preferred. The powder should be stored in sealed moisture-barrier bags at ≤ 25 °C and protected from light.

Process incompatibilities include strong alkaline salts at pH above 8.0, ferric chloride, copper sulfate, and strong oxidizing agents. These substances accelerate oxidative browning of the extract matrix and may reduce marker assay. Contact with organic solvents containing more than 30% acetone should be avoided unless pilot-scale compatibility data support the use. In tableting, pregelatinized starch and copovidone are preferred binders; sodium starch glycolate and croscarmellose sodium may be used as disintegrants, but their hygroscopicity should be considered in tropical climates. Aqueous film coating is preferred because organic-solvent coating can alter the botanical extract surface and affect dissolution. The material should not be combined with trace mineral premixes containing ferric or cupric salts without prior segregation testing.